UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers.
FAIL · Does not pass the screen
45.50 USD
At the last full screen 2026-08-27
Screened 2026-08-27 · the tape above runs as of 10:31 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markdown label.
UroGen Pharma Ltd. holds its Markdown at $45.50. The statistical read favours the sellers, held for 118 days.
As held on the ledger · 2026-08-27
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 118 days
Price at the screen
$45.50
Valuation
N/A trailing · 16.28 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.58
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
64.02%
Below 33%
Interest-bearing debt is 64.0% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
4.84%
Below 33%
Cash held in interest-bearing accounts and securities is 4.8% of assets, under the one-third limit.
Pass
Receivables
71.75%
Below 49%
Money owed to the company is 71.8% of assets, above the 49% limit.
Fail
Revenue purity
5.43%
Below 5%
5.4% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-08-27 screen. The gold marker is the market price at the same screen. A 32.4% margin of safety to the base estimate.
Third-party analyst targets: 8 covering, consensus Strong Buy. The average target sits +30% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-08-27 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Cancer gel developer priced beyond its promise
Picture a reverse-thermal gel designed to cling to bladder walls and deliver chemo locally. UroGen has turned that idea into early revenue that leapt 152 percent, yet the business still posts a 95 percent loss margin and trades at 29 times forward earnings, eight percent above our calculated fair value.
We therefore pass. The strong-buy analyst chorus and 44 dollar median target reflect hope in upcoming data, but they ignore the thin margin of safety and the unknown competitive durability of the hydrogel platform once larger rivals enter the same niche.
Risk sits in typical biotech fashion around clinical setbacks, dilution and cash burn that could widen quickly if trials disappoint. Currency and regulatory swings in specialty oncology add further volatility to an already fragile setup. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
URGN trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-15Markup$49.00+64.9%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 64.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 297%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (8 analysts) rates it strong buy, with a mean price target of $37.
2026-07-18Markup$29.72+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 297%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (8 analysts) rates it strong buy, with a mean price target of $37.
2026-07-03Markup$29.72+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markup$29.72Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
